CS Diagnostic
CS Diagnostics Corp. (CSDX) develops and distributes the MEDUSA smart disinfectant system, the FDA-approved CS Protect-Hydrogel for prostate cancer radiotherapy, and complementary medical devices, serving healthcare institutions, fitness and education facilities, luxury hospitality, and government health ministries globally through multi-channel B2B and B2C distribution.
- Company typePublic
- Founded2009
- HeadquartersCheyenne, United States
- Headcount1–10
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What CS Diagnostic does
CS Diagnostics Corp. (OTCQB: CSDX), a US-domiciled holding entity within the CS Group conglomerate founded by Thomas Fahrhoefer in 2009 in Germany, develops and distributes medical-grade disinfectant products, an FDA-approved hydrogel for cancer radiotherapy, and complementary medical devices. Its core proprietary offerings are MEDUSA SDP — a smart disinfectant system in wet-wipe and liquid formats (500ml and 5-liter bulk) claiming up to 10 days of antimicrobial surface protection and 99.99% germ-kill efficacy, available in alcohol-based and alcohol-free formulations — and CS Protect-Hydrogel, a sterile pre-packaged tissue spacer for prostate cancer radiotherapy that protects healthy tissue during radiation treatment. The portfolio is rounded out by MRI/CT injectors, high-pressure syringes, MultiCSafe and DoubleCSafe tube systems, a Well+ eLearning platform, and VitaLab infection-testing solutions.
The company operates a multi-channel B2B and B2C go-to-market. Institutional clients (hospitals, gyms, schools, corporate customers) are served via direct sales and bulk logistics through DHL, while consumer markets are reached through physical retail in the UAE and Germany, online marketplaces, and a direct-to-consumer website, with FedEx Dubai handling retail deliveries. Manufacturing is outsourced to strategic partners Emirate Wet Wipes LLC and Gulf Centre Group Factory, and the company operates through wholly-owned subsidiaries CS Diagnostics Pharma GmbH (Germany), CS Interpharm LLC (UAE/GCC), and CSi Turkey. Reported headcount is 1-10 employees and the company is currently conducting a Private Placement REG D 506(c) offering.
Revenue is not disclosed and MEDUSA SDP is described as recently transitioning from development to commercial production (January 2026). Pricing is quote-based for institutional accounts and unit-based for consumer channels, with no public price points. The company pursues a hybrid segmentation across healthcare institutions, fitness and education facilities, oncology/radiotherapy, luxury hospitality (Ritz-Carlton Dubai as a flagship reference), and government health ministries (Zimbabwe engagement). US public-company reporting infrastructure is being built via a PCAOB-registered auditor appointment for 2025 group financials.
CS Diagnostic firmographics
Firmographics- Name
- CS Diagnostic
- Legal name
- CS Diagnostics Corp. Corporation
- Website
- https://csdcorp.us
- Company type
- Public
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- CS Diagnostics Corp. (CSDX) develops and distributes the MEDUSA smart disinfectant system, the FDA-approved CS Protect-Hydrogel for prostate cancer radiotherapy, and complementary medical devices, serving healthcare institutions, fitness and education facilities, luxury hospitality, and government health ministries globally through multi-channel B2B and B2C distribution.
- Ownership category
- akta.pro rank
CS Diagnostic industry classification
Industry- Product category
- Medical Devices and Infection Control
- NAICS
- Medical Equipment and Supplies Manufacturing (3391), Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)
- akta.pro primary industry
- Medical & Hygiene Disposables (Underpads, Disposable Washcloths, Bed Bath Products) (CRADALAK)
Keywords
Where CS Diagnostic is headquartered
LocationHeadquarters
- HQ city
- Cheyenne
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
CS Diagnostic business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Marketing or Sales, Operations, Personnel, Technology or R&D
Revenue model
- MEDUSA SDP Product Sales: Sale of medical-grade wet wipes and liquid disinfectants through institutional B2B and consumer B2C channels. Products manufactured by partners Emirate Wet Wipes LLC and Gulf Centre Group Factory. Distribution via retail stores in UAE and Germany, online marketplaces, and direct-to-consumer website.
- Pharmaceutical Distribution: Wholesale distribution of pharmaceuticals and medical devices through CS Diagnostics Pharma GmbH. Company plays role in healthcare supply chain ensuring widespread access to essential medications with over 25 years of sales experience.
- Medical Technology Products: Sale of proprietary medical technology products including injectors for MRI and CT, high-pressure syringes, MultiCSafe and DoubleCSafe tube systems, and CS Protect-Hydrogel for cancer treatment.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Institutional B2B pricing (hospitals, gyms, schools) |
| Unit Pricing | Pay-as-you-go | Consumer B2C pricing (retail and online) |
Go-to-market motion3 records
Distribution channels6 records
Marketing channels7 records
CS Diagnostic product offering
Product offeringCore offering
CS Diagnostics Corp. develops, manufactures, and distributes proprietary medical products including the MEDUSA SDP smart disinfectant system (medical-grade wet wipes and liquid disinfectants providing up to 10 days of antimicrobial surface protection) and CS Protect-Hydrogel (an FDA-approved hydrogel tissue spacer for prostate cancer radiotherapy). The company also distributes complementary medical devices such as MRI/CT injectors, high-pressure syringes, and tube systems, alongside pharmaceutical wholesale distribution through its German subsidiary.
Product overview
CS Diagnostics Corp. offers a diversified medical technology portfolio centered around two core products: MEDUSA SDP (a smart disinfectant system with medical-grade wet wipes and liquid formulations providing up to 10 days of surface protection) and CS Protect-Hydrogel (FDA-approved hydrogel tissue spacer for prostate cancer radiotherapy protection). The company also supplies complementary medical devices including MRI/CT injectors, high-pressure syringes, and tube systems (MultiCSafe, DoubleCSafe), alongside the Well+ eLearning platform for medical professionals and VitaLab infection testing solutions. The portfolio serves healthcare, institutional, and consumer markets globally through wholesale distribution and strategic partnerships.
Differentiator
Problem solved
Functional benefit
Brands
- MEDUSA SDP: Smart disinfectant product line - medical-grade wet wipes and liquid disinfectants that provide up to 10 days of protection against bacteria, viruses, and fungi. Available in alcohol-based and alcohol-free formulations.
- CS Protect-Hydrogel
Products and services
- MEDUSA SDP
Quantifiable outcome
- MEDUSA proven effective for up to 10 days surface protection
- +2 more outcomes
Companies that use CS Diagnostic
Customer profileNamed customers3 records
Segments6 records
Ideal customer profiles6 records
CS Diagnostic technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
CS Diagnostic partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered minor, core and flagship.
- Shah Teelani & AssociatesminorDubai-based PCAOB-registered audit firm appointed to consolidate and audit the Group's 2025 financial statements for CS Diagnostics Corp., CS Interpharm GT LLC, and CS Diagnostics Pharma GmbH. Engagement part of strategy to strengthen financial governance and align reporting with US public company standards.
- Emirate Wet Wipes LLCcoreStrategic manufacturing partnership for MEDUSA SDP product line. Emirate Wet Wipes LLC manufactures disinfectant wet wipes as part of transition from development to commercial production. Partnership marked as major commercialization milestone supporting global launch.
- Gulf Centre Group FactorycoreStrategic manufacturing partnership for MEDUSA SDP product line. Gulf Centre Group Factory produces bulk liquid formulations in 500ml and 5-liter formats. Partnership marked as major commercialization milestone supporting global launch across healthcare, institutional, and consumer markets.
- CS Group SubsidiariescoreCorporate structure includes CS Diagnostics Corp. (US), CS Interpharm GT LLC (UAE/GCC), CS Diagnostics Pharma GmbH (Germany), and CSi Turkey. Group companies collaborate on product development, distribution, and regulatory approval processes across multiple regions.
- FedEx DubaicoreCSinterpharm partnered with FedEx Dubai combining worldwide logistics and shipping capabilities with CSinterpharm's expertise in medical supplies. Partnership focuses on faster, safer, and more efficient delivery of advanced medical innovations around the world. FedEx's extensive infrastructure and advanced technology strengthens CSinterpharm's distribution network, reduces transit times, and ensures safe delivery to even remote locations.
- The Ritz-Carlton DubaiflagshipCSinterpharm partnership with The Ritz-Carlton Dubai for first delivery of MEDUSA smart disinfectant product. Collaboration marks beginning of promising long-term partnership poised to transform hygiene standards in hospitality industry. Initial delivery of 25 one-liter bottles for demonstration. Eco-friendly MEDUSA supports hotel's sustainability initiatives.
- Zimbabwe Embassy in UAEminorChairman Thomas Fahrhoefer visited Zimbabwe Embassy in Abu Dhabi to discuss healthcare initiatives supporting Zimbabwe's healthcare infrastructure. Presentations included MEDUSA smart disinfectant, VitaLab test solutions, and medical care product delivery. Part of initiative for international cooperation and innovative healthcare solutions for underserved regions.
- Dubai Club for People of DeterminationminorCSinterpharm is a proud supporter of the Dubai Club for People of Determination. CS Group's regional arm contributes to community betterment by supporting initiatives that promote wellness and development in healthcare and sports. Collaboration reflects shared vision of improving quality of life for individuals with disabilities.
Scale indicators5 records
Recent moves7 records
Expansion highlights7 records
CS Diagnostic competitors and assessment
Company assessmentBroad incumbents
- McKesson: McKesson is a global pharmaceutical and medical-product wholesaler that competes with CS Diagnostics Pharma GmbH's pharmaceutical distribution business across Europe and adjacent markets.
- 3M Health Care: 3M's Health Care division spans infection prevention, drug delivery, and medical supplies, creating overlapping offerings with MEDUSA SDP surface disinfection and CS Diagnostics' broader medical device catalog.
- Reckitt Benckiser: Reckitt owns Lysol and Dettol, the dominant consumer disinfectant brands globally; it represents the incumbent benchmark CS Diagnostics' MEDUSA SDP must differentiate against in retail and institutional channels.
- Clorox Company: Clorox is a broad incumbent in disinfectants and surface sanitization, with a comparable consumer and institutional disinfectant portfolio competing for the same shelf and contract slots targeted by MEDUSA SDP.
Direct peers
- GOJO Industries: GOJO Industries, maker of Purell, is a focused player in healthcare and institutional hand hygiene and surface disinfection, directly comparable to MEDUSA SDP in the infection-prevention use case.
- Guerbet: Guerbet is a specialized contrast media and injector manufacturer for radiology, directly comparable to CS Diagnostics' MRI/CT injectors and high-pressure syringes for imaging workflows.
- Boston Scientific: Boston Scientific markets SpaceOAR, an FDA-approved hydrogel spacer for prostate cancer radiotherapy, which directly competes with CS Diagnostics' CS Protect-Hydrogel in the same indication and clinical use case.
- Ecolab: Ecolab is a global leader in institutional disinfection and hygiene solutions for healthcare, hospitality, and food service — markets where CS Diagnostics is positioning MEDUSA SDP as a long-acting alternative.
- Bayer (Medrad): Bayer's Medrad division manufactures MRI and CT contrast injectors, which are direct competitors to the MRI/CT injectors and high-pressure syringes in CS Diagnostics' medical device portfolio.
Emerging players
- Palette Life Sciences: Palette Life Sciences markets Barrigel, another rectal spacer hydrogel for prostate radiotherapy; it is an emerging competitor in the same niche use case as CS Protect-Hydrogel.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
CS Diagnostic social profiles
Digital presenceCS Diagnostic financial estimates
Financial estimateRevenue estimate
Valuation estimate
CS Diagnostic leadership team
Management profileNumber of profiles
Profiles2 records
CS Diagnostic subsidiaries and ownership
Company hierarchySubsidiaries3 records
CS Diagnostic funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CS Diagnostic M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CS Diagnostic
What does CS Diagnostic do?
CS Diagnostics Corp. develops, manufactures, and distributes proprietary medical products including the MEDUSA SDP smart disinfectant system (medical-grade wet wipes and liquid disinfectants providing up to 10 days of antimicrobial surface protection) and CS Protect-Hydrogel (an FDA-approved hydrogel tissue spacer for prostate cancer radiotherapy). The company also distributes complementary medical devices such as MRI/CT injectors, high-pressure syringes, and tube systems, alongside pharmaceutical wholesale distribution through its German subsidiary.
Is CS Diagnostic a public or private company?
CS Diagnostic is a public company. It is classified as public and is currently operating.
When was CS Diagnostic founded?
CS Diagnostic was founded in 2009. It employs 1 to 10 people.
Where is CS Diagnostic based?
CS Diagnostic is headquartered in Cheyenne, United States, in the North America region.
How does CS Diagnostic make money?
Three revenue lines are on record. MEDUSA SDP Product Sales are the primary driver. The others are pharmaceutical Distribution and medical Technology Products.
Who are CS Diagnostic's main competitors?
Broad incumbents on record are McKesson, 3M Health Care, Reckitt Benckiser and Clorox Company. Direct peers are GOJO Industries, Guerbet, Boston Scientific, Ecolab and Bayer (Medrad). Palette Life Sciences is listed as an emerging player.
Does CS Diagnostic have an API?
No public API is recorded for CS Diagnostic.
What industry is CS Diagnostic in?
CS Diagnostic's product category is Medical Devices and Infection Control. Its primary akta.pro industry code is CRADALAK, Medical & Hygiene Disposables (Underpads, Disposable Washcloths, Bed Bath Products). Its NAICS code is 3391 and its SIC code is 3841.